Genentech takes the health and safety of our patients, customers, employees, and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more information, please visit our COVID-19 response page.

We use cookies to give you the best online experience. By using our website you agree to our use of cookies in accordance with our cookie policy. Learn more

Hemlibra
For Patients and Caregivers
  • Publications and Scientific Presentations
  • Guidelines and Recommendations
  • Medical Resource Links
  • FAQ
  • Search Result(current)
  • Prescribing Information
Medical Information Inquiries Logout
Roche logo
  • Emicizumab Data by Topic
  • Congresses
For Patients and Caregivers
  • Emicizumab Data by Topic
  • Congresses
Prescribing Information Medical info request
Link to third party site

The link you have selected will take you away from this site to one that is not owned or controlled by Roche, F. Hoffmann-La Roche Ltd makes no representation as to the accuracy of the information contained on sites we do not own or control. Roche does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

364 Search Results

Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real-world cases to support shared decision-making

Mason JA, Young G.  [published online ahead of print Jun 4] Haemophilia. 2021 Jun 4. doi: 10.1111/hae.14353

ST‐Segment Elevation Myocardial Infarction (STEMI) and Pulmonary Embolism in a Hemophilia A Patient Receiving Emicizumab and recombinant Activated Factor VII

Gundabolu K, Goldsweig A, Bhatt VR, Koepsell SA, Harper JL. Haemophilia. 2020;26(1):e5-e8.

Management of children with hemophilia A: How emicizumab has changed the landscape

Young G. J Thromb Haemost. 2021 Jul;19(7):1629-1637.

Emicizumab for routine prophylaxis to prevent bleeding episodes in patients with hemophilia A

Díaz-Ricart M, Isola IM, Escolar G. Drugs Today (Barc). 2018;54(10):591-600.

Emicizumab-mediated haemostatic function in patients with haemophilia A is down-regulated by activated protein C through inactivation of activated factor V.

Yada K, Nogami K, Shinozawa K, et al. Br J Haematol 2018;183:257–266.

  • Previous button
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • Next button

Contact Us
|
Privacy Policy
|
Terms & Conditions
|
Cookies Settings
© Genentech USA, Inc. All rights reserved.
This site is intended for US Healthcare Professionals only.
Roche